Transgenomic's Q4 Revenues Drop 6 Percent; Swings to Loss | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Wednesday that its fourth-quarter revenues declined 6 percent and it swung from a profit in the 2007 fourth quarter to a loss.

The Omaha, Neb.-based pharmacogenomics assay developer and lab services firm had revenues of $6.1 million for the three-month period ended December 31, compared to revenues of $6.5 million for the fourth quarter of 2007.

It swung to a net loss of $219,000, or $.00, per share, from a profit of $212,000, or $.00 per share, in the fourth quarter of 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.